AN OPEN-LABEL, PHASE I/IIA STUDY OF VB10.NEO (DIRECT-01) IN COMBINATION WITH CHECKPOINT BLOCKADE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS INCLUDING MELANOMA, NSCLC, RENAL CELL CARCINOMA, UROTHELIAL CANCER OR SSCHN | Atlanta, April 2019
1673
portfolio_page-template-default,single,single-portfolio_page,postid-1673,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.0.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

AN OPEN-LABEL, PHASE I/IIA STUDY OF VB10.NEO (DIRECT-01) IN COMBINATION WITH CHECKPOINT BLOCKADE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS INCLUDING MELANOMA, NSCLC, RENAL CELL CARCINOMA, UROTHELIAL CANCER OR SSCHN

Atlanta, April 2019